呼吸器疾患ワクチンの市場規模、シェア、動向分析レポート：タイプ別、年齢層別、感染症別、流通チャネル別、地域別、セグメント予測、2023年～2030年

呼吸器疾患ワクチン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の呼吸器疾患ワクチン市場規模は2023年から2030年にかけてCAGR 1.21%で拡大し、2030年には703億米ドルに達する見込みです。

呼吸器疾患ワクチン市場の成長は、ワクチン接種の重要性に関する意識の高まり、呼吸器感染症の発生率の上昇、ワクチン技術の進歩に起因しています。さらに、COVID-19のパンデミックは、呼吸器系ワクチンの重要性に大きな牽引力をもたらし、市場をさらに加速させています。

呼吸器系ワクチン、特にインフルエンザや肺炎をターゲットとしたワクチンは、ヘルスケアシステムの負担を軽減し、COVID-19との重複感染リスクを最小限に抑えるために不可欠です。ウイルスの蔓延を防ぎ、アウトブレイクの発生を防ぐため、ヘルスケア提供者はインフルエンザなどの呼吸器病原体から個人を守るワクチン接種に注力しています。近年、呼吸器系ワクチン市場は、ワクチン技術の進歩、特にSARS-CoV-2を標的としたワクチン開発により、大きく成長しています。COVID-19ワクチンの開発、承認、配備の成功は、呼吸器系の脅威に迅速に対応する科学界の能力を実証し、呼吸器系ワクチンの研究開発における将来の進歩への道を開いた。

さらに、インフルエンザワクチンの入手可能性、普及、実施状況を監視するための国レベル、世界レベルでの政府の支援と監視は、市場の成長を促進する重要な要因となっています。さらに、新規ワクチンの市場導入に重点を置く著名な主要企業による投資の増加が、市場の成長に寄与しています。例えば、ファイザーは最近、mRNAベースのインフルエンザワクチンの第3相臨床試験を2022年9月に開始する計画を明らかにしました。この試験には、米国の18歳以上の25,000人のコホートが参加する予定です。

さらに、様々な呼吸器疾患ワクチンの開発・製剤化に携わる主な企業は、新規ワクチンの開発や市場競争力の維持のため、提携や共同研究に注力しています。加えて、植物由来の医薬品が提供する自然療法への関心の高まりが、予測期間中に市場を押し上げると予想されます。さらに、医薬品需要の高まりに対応するため、多くの企業が地理的拡大や流通に関与しています。例えば、2023年5月、ファイザー社は、60歳以上の高齢者層におけるRSVによる下気道疾患の予防を目的としたRSVワクチンABRYSVOのFDA承認を取得しました。

呼吸器疾患ワクチン市場レポートハイライト

• タイプ別では、ウイルス性呼吸器疾患の有病率の増加により、ウイルス性ワクチン分野が2022年に最大の売上シェアを占めました。
• 年齢層別では、小児人口向けのワクチン製剤の増加により、小児セグメントが予測期間中に最も速い成長率を示すと予測されます。
• 感染症別では、COVID-19ウイルスの蔓延を阻止するワクチン開発の必要性が高まっていることから、2022年にはCOVID-19セグメントが優位を占めました。
• 同市場で事業を展開する主要企業は、その存在感を維持するため、地理的拡大と製品上市に常に注力しています。
• 北米は2022年に最大の収益シェアを占めたが、これは主要プレイヤーの存在、ヘルスケアインフラの台頭、慢性疾患の症例の増加、適切なワクチン接種サービスの利用が可能であることに起因しています。

目次

第1章 呼吸器疾患ワクチン市場：調査手法と範囲

• 市場セグメンテーションと範囲
  • 地域の範囲
  • 推定・予測のタイムライン
  • 目的
• 調査手法
• 情報調達
  • 購入したデータベース
  • Gvrの内部データベース
  • 二次情報
  • 1次調査
• 情報またはデータ分析
  • データ分析モデル
• 市場の形成と検証
• モデル詳細
  • 商品フロー分析
• 二次情報のリスト
• 略語のリスト

第2章 呼吸器疾患ワクチン市場：エグゼクティブサマリー

• 市場スナップショット
• タイプと年齢層のスナップショット
• 流通チャネルと感染のスナップショット
• 競合情勢のスナップショット

第3章 呼吸器疾患ワクチン市場：業界の展望

• 市場系統の見通し
  • 親市場の系統の見通し
  • 関連/不随的な市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因
  • 市場抑制要因分析
• SWOT分析、要因別（政治・法律、経済・技術）
• 業界分析- ポーター
• 償還と規制のシナリオ
• 大規模な取引と戦略的提携
  • 新製品の発売
  • 取得
  • 拡大
  • パートナーシップ
  • マーケティングとプロモーション

第4章 呼吸器疾患ワクチン市場：競合情勢

• 主要市場参入企業による最近の動向と影響分析
  • アンゾフ・マトリクス
• 企業の分類
  • イノベーター
• ベンダー情勢
  • 主要な販売代理店とチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2022 年
• 公開会社
  • 競合ダッシュボード分析
• 非公開会社
  • 主要な新興企業のリスト
• 地域ネットワークマップ

第5章 呼吸器疾患ワクチン市場：タイプビジネス分析

• 定義と範囲
• タイプ市場シェア分析、2022年および2030年
• 世界の呼吸器疾患ワクチン市場、タイプ別、2018年から2030年
• 呼吸器疾患ワクチン市場：タイプ変動分析
• ウイルスワクチン
• 細菌ワクチン
• 混合ワクチン

第6章 呼吸器疾患ワクチン市場：年齢層別ビジネス分析

• 定義と範囲
• 年齢層の市場シェア分析、2022年および2030年
• 世界の呼吸器疾患ワクチン市場、年齢層別、2018年から2030年
• 呼吸器疾患ワクチン市場：年齢層の変動分析
• 小児
• 成人

第7章 呼吸器疾患ワクチン市場：感染症ビジネス分析

• 定義と範囲
• 感染症市場シェア分析、2022年および2030年
• 世界の呼吸器疾患ワクチン市場、感染症別、2018年から2030年
• 呼吸器疾患ワクチン市場：感染変動分析
• COVID-19
• インフルエンザ
• RSウイルス
• 肺炎
• その他

第8章 呼吸器疾患ワクチン市場：流通チャネルビジネス分析

• 定義と範囲
• 流通チャネル市場シェア分析、2022年および2030年
• 世界の呼吸器疾患ワクチン市場、流通チャネル別、2018年から2030年
• 呼吸器疾患ワクチン市場：流通チャネルの変動分析
• 病院および小売薬局
  • 病院および小売薬局市場推計・予測、2018年から2030年
• 政府のサプライヤー
• その他

第9章 呼吸器疾患ワクチン市場：地域ビジネス分析

• 定義と範囲
• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 地域市場のスナップショット
• SWOT分析、要因別（政治・法律、経済・技術）
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ
• 市場規模、予測、動向分析、2022年から2030年まで
• 北米
  • 北米呼吸器疾患ワクチン市場推計・予測、2018年から2030年
  • 米国
  • カナダ
• 欧州
  • 欧州呼吸器疾患ワクチン市場、2018～2030年
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋地域
  • アジア太平洋呼吸器疾患ワクチン市場、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • タイ
  • オーストラリア
• ラテンアメリカ
  • ラテンアメリカの呼吸器疾患ワクチン市場、2018年から2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの呼吸器疾患ワクチン市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 呼吸器疾患ワクチン市場：企業プロファイリング

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析、2022年
• 企業プロファイル
  • Gsk Plc.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute Of India Pvt. Ltd.
  • Sinovac
  • Bavarian Nordic
  • Merck & Co., Inc.
  • Astrazeneca
  • Emergent
  • Novavax
  • Inovio Pharmaceuticals
  • Moderna Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Global Respiratory Disease Vaccine Market, By Region, 2018 - 2030 (USD Million)
• Table 4 Global Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 5 Global Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 6 Global Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 7 Global Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 10 North America Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 11 North America Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 12 North America Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 15 U.S. Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 16 U.S. Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 18 Canada Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 19 Canada Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 20 Canada Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 21 Europe Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 22 Europe Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 23 Europe Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 24 Europe Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 25 Europe Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Germany Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 27 Germany Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 28 Germany Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 29 Germany Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 UK Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 31 UK Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 32 UK Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 33 UK Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 France Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 35 France Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 36 France Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 37 France Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Italy Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 39 Italy Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 40 Italy Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 41 Italy Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 Spain Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 43 Spain Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 44 Spain Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 45 Spain Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Denmark Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 47 Denmark Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 48 Denmark Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 49 Denmark Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 Sweden Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 51 Sweden Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 52 Sweden Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 53 Sweden Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 Norway Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 55 Norway Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 56 Norway Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 57 Norway Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Japan Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 64 Japan Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 65 Japan Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 66 Japan Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 China Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 68 China Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 69 China Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 70 China Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 71 India Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 72 India Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 73 India Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 74 India Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 South Korea Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 76 South Korea Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 77 South Korea Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 78 South Korea Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Australia Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 80 Australia Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 81 Australia Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 82 Australia Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 Thailand Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 84 Thailand Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 85 Thailand Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 86 Thailand Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 87 Latin America Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 88 Latin America Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 89 Latin America Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 90 Latin America Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 91 Latin America Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Brazil Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 93 Brazil Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 94 Brazil Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 95 Brazil Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 96 Mexico Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 97 Mexico Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 98 Mexico Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 99 Mexico Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 100 Argentina Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 101 Argentina Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 102 Argentina Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 103 Argentina Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Respiratory Disease Vaccine Market, By Country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 113 South Africa Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 114 South Africa Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 115 South Africa Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 116 South Africa Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 117 UAE Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 118 UAE Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 119 UAE Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 120 UAE Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 121 Kuwait Respiratory Disease Vaccine Market, By Type, 2018 - 2030 (USD Million)
• Table 122 Kuwait Respiratory Disease Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
• Table 123 Kuwait Respiratory Disease Vaccine Market, By Infection, 2018 - 2030 (USD Million)
• Table 124 Kuwait Respiratory Disease Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Respiratory Disease Vaccine Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Respiratory disease vaccine market: Type outlook and key takeaways
• Fig. 15 Respiratory disease vaccine market: Type movement analysis & market share 2022 & 2030
• Fig. 16 Viral vaccines market, 2018 - 2030 (USD Million)
• Fig. 17 Bacterial vaccine market, 2018 - 2030 (USD Million)
• Fig. 18 Combination vaccine market, 2018 - 2030 (USD Million)
• Fig. 19 Respiratory disease vaccine market: Age group outlook and key takeaways
• Fig. 20 Respiratory disease vaccine market: Age group movement analysis & market share 2022 & 2030
• Fig. 21 Pediatric market, 2018 - 2030 (USD Million)
• Fig. 22 Adult market, 2018 - 2030 (USD Million)
• Fig. 23 Respiratory disease vaccine market: Infection outlook and key takeaways
• Fig. 24 Respiratory disease vaccine market: Infection movement analysis & market share 2022 & 2030
• Fig. 25 COVID-19 market, 2018 - 2030 (USD Million)
• Fig. 26 Influenza market, 2018 - 2030 (USD Million)
• Fig. 27 Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
• Fig. 28 Pneumonia market, 2018 - 2030 (USD Million)
• Fig. 29 Others antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 30 Respiratory disease vaccine market: Distribution channel outlook and key takeaways
• Fig. 31 Respiratory disease vaccine market: Distribution channel movement analysis & market share 2022 & 2030
• Fig. 32 Hospital & retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Government suppliers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Regional Marketplace: Key Takeaways
• Fig. 36 Regional Outlook, 2022 & 2030
• Fig. 37 Regional Market Dashboard
• Fig. 38 Regional Market Place: Key Takeaways
• Fig. 39 North America, SWOT Analysis
• Fig. 40 Europe, SWOT Analysis
• Fig. 41 Asia Pacific, SWOT Analysis
• Fig. 42 Latin America, SWOT Analysis
• Fig. 43 MEA, SWOT Analysis
• Fig. 44 North America
• Fig. 45 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 46 U.S. Key Country Dynamics
• Fig. 47 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 48 Canada Key Country Dynamics
• Fig. 49 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 50 Europe
• Fig. 51 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 52 UK Key Country Dynamics
• Fig. 53 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 54 Germany Key Country Dynamics
• Fig. 55 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 56 France Key Country Dynamics
• Fig. 57 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 58 Italy Key Country Dynamics
• Fig. 59 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 60 Spain Key Country Dynamics
• Fig. 61 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 62 Denmark Key Country Dynamics
• Fig. 63 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 64 Sweden Key Country Dynamics
• Fig. 65 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 66 Norway Key Country Dynamics
• Fig. 67 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 68 Asia Pacific Key Country Dynamics
• Fig. 69 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 70 Japan Key Country Dynamics
• Fig. 71 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 72 China Key Country Dynamics
• Fig. 73 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 74 India
• Fig. 75 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 76 Australia Key Country Dynamics
• Fig. 77 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 78 Thailand Key Country Dynamics
• Fig. 79 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 80 South Korea Key Country Dynamics
• Fig. 81 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 82 Latin America
• Fig. 83 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 84 Brazil Key Country Dynamics
• Fig. 85 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 86 Mexico Key Country Dynamics
• Fig. 87 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 88 Argentina Key Country Dynamics
• Fig. 89 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 90 MEA
• Fig. 91 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 92 South Africa Key Country Dynamics
• Fig. 93 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 94 Saudi Arabia Key Country Dynamics
• Fig. 95 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 96 UAE Key Country Dynamics
• Fig. 97 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 98 Kuwait Key Country Dynamics
• Fig. 99 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 100 Strategy Mapping

Respiratory Disease Vaccine Market Growth & Trends

The global respiratory disease vaccine market size is expected to reach USD 70.30 billion by 2030, expanding at a CAGR of 1.21% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the respiratory disease vaccine market is attributable to increasing awareness associated with the importance of vaccination, the rising incidence of respiratory infections, and advancements in vaccine technology. Moreover, the COVID-19 pandemic has brought significant traction to the importance of respiratory vaccines which has further accelerated the market.

Respiratory vaccines, particularly those targeting influenza and pneumonia, are vital in reducing the burden on healthcare systems and minimizing the risk of co-infections with COVID-19. In order to prevent the spread of the virus and prevent the occurrence of outbreaks healthcare providers have been focusing on vaccination to protect individuals against respiratory pathogens like influenza. In recent years, the respiratory vaccine market has witnessed substantial growth attributed to advancements in vaccine technology, specifically in the development of vaccines targeting SARS-CoV-2. The successful development, approval, and deployment of COVID-19 vaccines have demonstrated the capacity of the scientific community to respond rapidly to respiratory threats and have paved the way for future advancements in respiratory vaccine research and development.

Moreover, government backing and surveillance at both national and global levels to monitor the availability, dissemination, and implementation of influenza vaccines is a crucial factor driving the growth of the market. Additionally, increased investments by prominent key players with a major focus on the introduction of novel vaccines into the market have contributed to the growth of the market. For instance, Pfizer recently disclosed their plans to commence Phase 3 clinical trials for their mRNA-based influenza vaccine in September 2022. This trial will involve a cohort of 25,000 individuals aged 18 and above from the U.S.

Furthermore, key players involved in developing and formulating various respiratory disease vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the market. In addition, increasing interest in plant-based medicines owing to natural remedies offered by them is expected to boost the market over the forecast period. Moreover, a number of players are involved in geographic expansion and distribution to meet the rising demand for medicinal products. For instance, in May 2023, Pfizer Inc. received FDA approval for ABRYSVO, a RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in the elderly population above the age of 60 years.

Respiratory Disease Vaccine Market Report Highlights

• Based on type, the viral vaccine segment held the largest revenue share in 2022 owing to the increasing prevalence of viral respiratory conditions
• Based on age group, the pediatric segment is expected to show the fastest growth rate over the forecast period owing to the rising formulation of vaccines for the pediatric population
• On the basis of infection, the COVID-19 segment dominated in 2022 due to the growing need for the development of a vaccine to stop the spread of the COVID-19 virus
• Key players operating in the market are constantly focusing on geographical expansion and product launches to maintain their presence
• North America held the largest revenue share in 2022 which can be attributed to the presence of key players, rising healthcare infrastructure, growing cases of chronic disorders, and availability of proper vaccination service

Table of Contents

Chapter 1 Respiratory Disease Vaccine Market: Methodology And Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Type Segment
    • 1.1.1.2 Age Group Segment
    • 1.1.1.3 Distribution Channel Segment
    • 1.1.1.4 Infection Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Respiratory Disease Vaccine Market: Executive Summary

• 2.1 Market Snapshot
• 2.2 Type And Age Group Snapshot
• 2.3 Distribution Channel And Infection Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Respiratory Disease Vaccine Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Lineage Outlook
  • 3.1.2 Related/Ancillary Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Drivers
    • 3.3.1.1 Increasing Prevalence Of Respiratory Diseases
    • 3.3.1.2 Growing Awareness And Focus On Prevention
    • 3.3.1.3 Increasing Government Initiatives And Immunization Programs
    • 3.3.1.4 Growing Geriatric Population
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Complex And Time-Consuming Regulatory Approval Process
    • 3.3.2.2 High Price Associated With Vaccines
• 3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
• 3.5 Industry Analysis - Porter's
• 3.6 Reimbursement & Regulatory Scenario
• 3.7 Major Deals & Strategic Alliances
  • 3.7.1 New Product Launch
  • 3.7.2 Acquisition
  • 3.7.3 Expansion
  • 3.7.4 Partnerships
  • 3.7.5 Marketing & Promotions

Chapter 4 Respiratory Disease Vaccine Market: Competitive Landscape

• 4.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 4.1.1 Ansoff Matrix
• 4.2 Company Categorization
  • 4.2.1 Innovators
    • 4.2.1.1 Market Differentiators
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
  • 4.3.3 Key Company Market Share Analysis, 2022
• 4.4 Public Companies
  • 4.4.1 Competitive Dashboard Analysis
• 4.5 Private Companies
  • 4.5.1 List Of Key Emerging Companies
• 4.6 Regional Network Map

Chapter 5 Respiratory Disease Vaccine Market: Type Business Analysis

• 5.1 Definition And Scope
• 5.2 Type Market Share Analysis, 2022 & 2030
• 5.3 Global Respiratory Disease Vaccine Market, By Type, 2018 To 2030
• 5.4 Respiratory Disease Vaccine Market: Type Movement Analysis
• 5.5 Viral Vaccine
  • 5.5.1 Viral Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6 Bacterial Vaccine
  • 5.6.1 Bacterial Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7 Combination Vaccine
  • 5.7.1 Combination Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Respiratory Disease Vaccine Market: Age Group Business Analysis

• 6.1 Definition And Scope
• 6.2 Age Group Market Share Analysis, 2022 & 2030
• 6.3 Global Respiratory Disease Vaccine Market, By Age Group, 2018 To 2030
• 6.4 Respiratory Disease Vaccine Market: Age Group Movement Analysis
• 6.5 Pediatric
  • 6.5.1 Pediatric Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6 Adult
  • 6.6.1 Adult Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Respiratory Disease Vaccine Market: Infection Business Analysis

• 7.1 Definition And Scope
• 7.2 Infection Market Share Analysis, 2022 & 2030
• 7.3 Global Respiratory Disease Vaccine Market, By Infection, 2018 To 2030
• 7.4 Respiratory Disease Vaccine Market: Infection Movement Analysis
• 7.5 Covid-19
  • 7.5.1 Covid-19 Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6 Influenza
  • 7.6.1 Influenza Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7 Respiratory Syncytial Virus (Rsv)
  • 7.7.1 Respiratory Syncytial Virus (Rsv) Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.8 Pneumonia
  • 7.8.1 Pneumonia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.9 Others
  • 7.9.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Respiratory Disease Vaccine Market: Distribution Channel Business Analysis

• 8.1 Definition And Scope
• 8.2 Distribution Channel Market Share Analysis, 2022 & 2030
• 8.3 Global Respiratory Disease Vaccine Market, By Distribution Channel, 2018 To 2030
• 8.4 Respiratory Disease Vaccine Market: Distribution Channel Movement Analysis
• 8.5 Hospital & Retail Pharmacies
  • 8.5.1 Hospital & Retail Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6 Government Suppliers
  • 8.6.1 Government Suppliers Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7 Others
  • 8.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 Respiratory Disease Vaccine Market: Regional Business Analysis

• 9.1 Definition & Scope
• 9.2 Regional Market Share Analysis, 2022 & 2030
• 9.3 Regional Market Dashboard
• 9.4 Regional Market Snapshot
• 9.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 9.5.1 North America
  • 9.5.2 Europe
  • 9.5.3 Asia Pacific
  • 9.5.4 Latin America
  • 9.5.5 MEA
• 9.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
• 9.7 North America
  • 9.7.1 North America Respiratory Disease Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.7.2 U.S.
    • 9.7.2.1 U.S. Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.7.2.2 Key Country Dynamics
    • 9.7.2.3 Regulatory Framework
    • 9.7.2.4 Competitive Scenario
  • 9.7.3 Canada
    • 9.7.3.1 Canada Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.7.3.2 Key Country Dynamics
    • 9.7.3.3 Regulatory Framework
    • 9.7.3.4 Competitive Scenario
• 9.8 Europe
  • 9.8.1 Europe Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
  • 9.8.2 Uk
    • 9.8.2.1 Uk Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.2.2 Key Country Dynamics
    • 9.8.2.3 Regulatory Framework
    • 9.8.2.4 Competitive Scenario
  • 9.8.3 Germany
    • 9.8.3.1 Germany Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.3.2 Key Country Dynamics
    • 9.8.3.3 Regulatory Framework
    • 9.8.3.4 Competitive Scenario
  • 9.8.4 Spain
    • 9.8.4.1 Spain Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.4.2 Key Country Dynamics
    • 9.8.4.3 Regulatory Framework
    • 9.8.4.4 Competitive Scenario
  • 9.8.5 France
    • 9.8.5.1 France Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.5.2 Key Country Dynamics
    • 9.8.5.3 Regulatory Framework
    • 9.8.5.4 Competitive Scenario
  • 9.8.6 Italy
    • 9.8.6.1 Italy Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.6.2 Key Country Dynamics
    • 9.8.6.3 Regulatory Framework
    • 9.8.6.4 Competitive Scenario
  • 9.8.7 Norway
    • 9.8.7.1 Norway Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.7.2 Key Country Dynamics
    • 9.8.7.3 Regulatory Framework
    • 9.8.7.4 Competitive Scenario
  • 9.8.8 Denmark
    • 9.8.8.1 Denmark Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.8.2 Key Country Dynamics
    • 9.8.8.3 Regulatory Framework
    • 9.8.8.4 Competitive Scenario
  • 9.8.9 Sweden
    • 9.8.9.1 Sweden Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.8.9.2 Key Country Dynamics
    • 9.8.9.3 Regulatory Framework
    • 9.8.9.4 Competitive Scenario
• 9.9 Asia Pacific
  • 9.9.1 Asia Pacific Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
  • 9.9.2 Japan
    • 9.9.2.1 Japan Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.9.2.2 Key Country Dynamics
    • 9.9.2.3 Regulatory Framework
    • 9.9.2.4 Competitive Scenario
  • 9.9.3 China
    • 9.9.3.1 China Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.9.3.2 Key Country Dynamics
    • 9.9.3.3 Regulatory Framework
    • 9.9.3.4 Competitive Scenario
  • 9.9.4 India
    • 9.9.4.1 India Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.9.4.2 Key Country Dynamics
    • 9.9.4.3 Regulatory Framework
    • 9.9.4.4 Competitive Scenario
  • 9.9.5 South Korea
    • 9.9.5.1 South Korea Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.9.5.2 Key Country Dynamics
    • 9.9.5.3 Regulatory Framework
    • 9.9.5.4 Competitive Scenario
  • 9.9.6 Thailand
    • 9.9.6.1 Thailand Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.9.6.2 Key Country Dynamics
    • 9.9.6.3 Regulatory Framework
    • 9.9.6.4 Competitive Scenario
  • 9.9.7 Australia
    • 9.9.7.1 Australia Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.9.7.2 Key Country Dynamics
    • 9.9.7.3 Regulatory Framework
    • 9.9.7.4 Competitive Scenario
• 9.10 Latin America
  • 9.10.1 Latin America Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
  • 9.10.2 Brazil
    • 9.10.2.1 Brazil Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.10.2.2 Key Country Dynamics
    • 9.10.2.3 Regulatory Framework
    • 9.10.2.4 Competitive Scenario
  • 9.10.3 Mexico
    • 9.10.3.1 Mexico Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.10.3.2 Key Country Dynamics
    • 9.10.3.3 Regulatory Framework
    • 9.10.3.4 Competitive Scenario
  • 9.10.4 Argentina
    • 9.10.4.1 Argentina Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.10.4.2 Key Country Dynamics
    • 9.10.4.3 Regulatory Framework
    • 9.10.4.4 Competitive Scenario
• 9.11 MEA
  • 9.11.1 MEA Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
  • 9.11.2 South Africa
    • 9.11.2.1 South Africa Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.11.2.2 Key Country Dynamics
    • 9.11.2.3 Regulatory Framework
    • 9.11.2.4 Competitive Scenario
  • 9.11.3 Saudi Arabia
    • 9.11.3.1 Saudi Arabia Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.11.3.2 Key Country Dynamics
    • 9.11.3.3 Regulatory Framework
    • 9.11.3.4 Competitive Scenario
  • 9.11.4 UAE
    • 9.11.4.1 UAE Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.11.4.2 Key Country Dynamics
    • 9.11.4.3 Regulatory Framework
    • 9.11.4.4 Competitive Scenario
  • 9.11.5 Kuwait
    • 9.11.5.1 Kuwait Respiratory Disease Vaccine Market, 2018 - 2030 (USD Million)
    • 9.11.5.2 Key Country Dynamics
    • 9.11.5.3 Regulatory Framework
    • 9.11.5.4 Competitive Scenario

Chapter 10 Respiratory Disease Vaccine Market: Company Profiling

• 10.1 Company Categorization
• 10.2 Strategy Mapping
  • 10.2.1 New Product Launch
  • 10.2.2 Partnerships
  • 10.2.3 Acquisition
  • 10.2.4 Collaboration
  • 10.2.5 Funding
• 10.3 Key Company Market Share Analysis, 2022
• 10.4 Company Profiles
  • 10.4.1 Gsk Plc.
    • 10.4.1.1 Company Overview
    • 10.4.1.2 Financial Performance
    • 10.4.1.3 Product Benchmarking
    • 10.4.1.4 Strategic Initiatives
  • 10.4.2 Johnson & Johnson Services, Inc.
    • 10.4.2.1 Company Overview
    • 10.4.2.2 Financial Performance
    • 10.4.2.3 Product Benchmarking
    • 10.4.2.4 Strategic Initiatives
  • 10.4.3 Pfizer Inc.
    • 10.4.3.1 Company Overview
    • 10.4.3.2 Financial Performance
    • 10.4.3.3 Product Benchmarking
    • 10.4.3.4 Strategic Initiatives
  • 10.4.4 Sanofi
    • 10.4.4.1 Company Overview
    • 10.4.4.2 Financial Performance
    • 10.4.4.3 Product Benchmarking
    • 10.4.4.4 Strategic Initiatives
  • 10.4.5 Serum Institute Of India Pvt. Ltd.
    • 10.4.5.1 Company Overview
    • 10.4.5.2 Product Benchmarking
    • 10.4.5.3 Strategic Initiatives
  • 10.4.6 Sinovac
    • 10.4.6.1 Company Overview
    • 10.4.6.2 Product Benchmarking
    • 10.4.6.3 Strategic Initiatives
  • 10.4.7 Bavarian Nordic
    • 10.4.7.1 Company Overview
    • 10.4.7.2 Financial Performance
    • 10.4.7.3 Product Benchmarking
    • 10.4.7.4 Strategic Initiatives
  • 10.4.8 Merck & Co., Inc.
    • 10.4.8.1 Company Overview
    • 10.4.8.2 Financial Performance
    • 10.4.8.3 Product Benchmarking
    • 10.4.8.4 Strategic Initiatives
  • 10.4.9 Astrazeneca
    • 10.4.9.1 Company Overview
    • 10.4.9.2 Financial Performance
    • 10.4.9.3 Product Benchmarking
    • 10.4.9.4 Strategic Initiatives
  • 10.4.10 Emergent
    • 10.4.10.1 Company Overview
    • 10.4.10.2 Financial Performance
    • 10.4.10.3 Product Benchmarking
    • 10.4.10.4 Strategic Initiatives
  • 10.4.11 Novavax
    • 10.4.11.1 Company Overview
    • 10.4.11.2 Financial Performance
    • 10.4.11.3 Product Benchmarking
    • 10.4.11.4 Strategic Initiatives
  • 10.4.12 Inovio Pharmaceuticals
    • 10.4.12.1 Company Overview
    • 10.4.12.2 Financial Performance
    • 10.4.12.3 Product Benchmarking
    • 10.4.12.4 Strategic Initiatives
  • 10.4.13 Moderna Inc.
    • 10.4.13.1 Company Overview
    • 10.4.13.2 Financial Performance
    • 10.4.13.3 Product Benchmarking
    • 10.4.13.4 Strategic Initiatives